Collect Product
Product Details
Synonyms
CD267, TACI, TNFRSF13B
Source
Human TACI (R119A, R122A), Fc Tag (TAI-H5253) is expressed from human 293 cells (HEK293). It contains AA Ser 2 - Thr 166 (Accession # O14836-1 (R119A,R122A)).
Predicted N-terminus: Ser 2
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 44.8 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Human TACI (R119A, R122A), Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Human TACI (R119A, R122A), Fc Tag (Cat. No. TAI-H5253) is more than 95% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human BAFF, His Tag at 2 μg/mL (100 μL/well) can bind Human TACI (R119A, R122A), Fc Tag (Cat. No. TAI-H5253) with a linear range of 0.2-2 ng/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
The present study demonstrated that, in NSCLC, a proliferation-inducing ligand (APRIL), B-cell maturation antigen (BCMA)and transmembrane activator and CAML interactor (TACI) proteins are abnormally expressed by immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting. In addition, the expression of APRIL, BCMA and TACI were observed to be involved in extracellular signal-regulated kinase (ERK)1/2 activation in A549 cells.
Frontier Progress
Drug Development Progress- English Name：
Tumor necrosis factor receptor superfamily member 13B
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
0 Details
- Highest R&D Stage：
Preclinical
Contact Us
Drug Candidate Licensing
